SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3158)1/9/2018 2:47:15 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 3202
 
>> At JPM, INCY was cautious on IDO1 <<

With all of the commentary about duration and deepening of the response, and with the slide showing data vs. historical for PD-1 alone? Emphasizing that nivo/epa results were as strong as pembro/epa? I got the opposite feel, that they were very strong re. IDO1.



To: Miljenko Zuanic who wrote (3158)1/9/2018 3:46:26 PM
From: DewDiligence_on_SI  Respond to of 3202
 
You're not the only one who's talking about a PFE-BMY hookup :- )


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News